Bilimsel çalışmalar

Prof. Dr. Fuat Demirkıran

145 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Minimally invasive pelvic exenteration: A safe alternative or a surgical challenge? A european multicentric, propensity-score matched analysis of the COREPEX study

    International Journal of Gynecological Cancer, 2026

    DOI 10.1016/j.ijgc.2025.103061 Kaynak: OpenAlex

  2. Pelvic exenteration for vulvar cancer: contemporary outcomes from a multinational cohort study

    European Journal of Surgical Oncology, 2026

    DOI 10.1016/j.ejso.2026.111468 PMID 41719783 1 atıf (Europe PMC) Kaynak: OpenAlex

  3. Adjuvant Chemotherapy and Survival After Pelvic Exenteration for Gynecologic Cancers in the COREPEX Study

    JAMA Network Open, 2026

    DOI 10.1001/jamanetworkopen.2026.20335 PMID 42360748 Açık erişimli tam metinKaynak: OpenAlex

  4. Adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies is associated with improved survival in patients with pelvic lymph node metastasis: a sub-analysis from the COREPEX study

    International Journal of Gynecological Cancer, 2026

    DOI 10.1016/j.ijgc.2025.103065 Kaynak: OpenAlex

  5. Pelvic exenteration for vulvar cancer: survival and morbidity outcomes from the COREPEX (complications and recurrence after pelvic exenteration) project

    International Journal of Gynecological Cancer, 2026

    DOI 10.1016/j.ijgc.2025.104413 Kaynak: OpenAlex

  6. Clinical predictors of early death and early relapse in advanced ovarian cancer: the SUROVA experience

    International Journal of Gynecological Cancer, 2026

    DOI 10.1016/j.ijgc.2026.104584 Kaynak: OpenAlex

  7. Pelvic exenteration versus radical hysterectomy as salvage treatment for pelvic central recurrent/persistent cervical cancer. A european database propensity-matched preliminary analysis

    International Journal of Gynecological Cancer, 2026

    DOI 10.1016/j.ijgc.2026.104575 Kaynak: OpenAlex

  8. Early death and early relapse in advanced ovarian cancer: distinct clinical phenotypes in the International SUROVA cohort

    International Journal of Gynecological Cancer, 2026

    DOI 10.1016/j.ijgc.2026.104897 PMID 42637597 Kaynak: OpenAlex

  9. Clinicopathologic and recurrence characteristics of leiomyoma with bizarre nuclei, which is rare type of uterine smooth macule tumors

    Ginekologia Polska, 2026

    DOI 10.5603/gpl.105587 PMID 42559999 Kaynak: OpenAlex

  10. Comparison of oncologic outcome of preoveratively presumed low-risk endometrial cancer patients who underwent only bilateral pelvic sentinel lymph node (SLN) removal and those who underwent pelvic lymphadenectomy in addition to bilateral pelvic SLN removal: Turkish Gynecologic Oncology Group (TRSGO-SLN-009)

    Journal of Gynecologic Oncology, 2025

    DOI 10.3802/jgo.2026.37.e23 PMID 41131800 Açık erişimli tam metinKaynak: OpenAlex

  11. Predictors and treatment of ısolated recurrence in vulvar cancer confined to the vulva or perineum

    Journal of Cancer Research and Therapeutics, 2025

    DOI 10.4103/jcrt.jcrt_1698_24 PMID 41004296 Kaynak: OpenAlex

  12. Adenomyosis and coexisting gynecologic pathologies: How often do they coexist?

    International Journal of Gynecology & Obstetrics, 2025

    DOI 10.1002/ijgo.70261 PMID 40448421 4 atıf (Europe PMC) Kaynak: OpenAlex

  13. SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2025.102688 PMID 41352872 19 atıf (Europe PMC) Kaynak: OpenAlex

  14. Complications and Recurrence After Pelvic Exenteration for Gynecologic Malignancies

    Obstetrics and Gynecology, 2025

    DOI 10.1097/aog.0000000000006051 PMID 40934517 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  15. Complications and recurrence after pelvic exenteration for gynecologic malignancies: Analysis of surgical complications from the COREPEX study

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2025.102820 PMID 41505868 1 atıf (Europe PMC) Kaynak: OpenAlex

  16. Complications And REcurrence After Pelvic Exenteration For Gynecologic Malignancies: Analysis Of Surgical Complications From The COREPEX Study

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2024.100091 Kaynak: OpenAlex

  17. COmplications And REcurrence After Pelvic Exenteration For Gynecologic Malignancies: Survival Analysis From The COREPEX Study.

    International Journal of Gynecological Cancer, 2025

    DOI 10.1016/j.ijgc.2024.100285 Kaynak: OpenAlex

  18. The relationship between histopathological data and molecular alterations with oncological outcomes in endometrioid-type endometrial cancers and a novel POLE mutation

    Journal of Gynecologic Oncology, 2025

    DOI 10.3802/jgo.2026.37.e6 PMID 40878396 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  19. Minimally invasive pelvic exenteration: a safe alternative or a surgical challenge? A propensity score matched analysis from the COREPEX study

    SSRN Electronic Journal, 2025

    DOI 10.2139/ssrn.5875989 Kaynak: OpenAlex

  20. Risk factors for the involvement of sentinel lymph nodes in endometrial cancer (TRSGO-SLN-010)

    International Journal of Gynecological Cancer, 2024

    DOI 10.1016/j.ijgc.2024.100041 PMID 39878290 2 atıf (Europe PMC) Kaynak: OpenAlex

  21. SUCCOR morbidity: complications in minimally invasive versus open radical hysterectomy in early cervical cancer

    International Journal of Gynecological Cancer, 2024

    DOI 10.1136/ijgc-2023-004657 PMID 38669163 9 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  22. 75 The association of molecular changes with oncological results on low and intermediate risk endometrial cancers and the effect of new risk groups created by combining histopathologİcal data and molecular changes on clinical management

    International Journal of Gynecological Cancer, 2024

    DOI 10.1136/ijgc-2024-esgo.293 Kaynak: OpenAlex

  23. Correspondence on: The risk of lymph node metastasis in the new FIGO 2018 stage IA cervical cancer with >7 mm diameter by Nicolai et al.

    Journal of Gynecologic Oncology, 2024

    DOI 10.3802/jgo.2024.35.e91 PMID 38768942 Açık erişimli tam metinKaynak: OpenAlex

  24. Impact of adjuvant treatments and risk factors on survival in 2023 FIGO stage IIB endometrial cancer patients: Turkish Gynecologic Oncology Group Study

    International Journal of Gynecological Cancer, 2024

    DOI 10.1136/ijgc-2024-005368 PMID 38839421 Kaynak: OpenAlex

  25. Primary Cytoreductive Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: the Primary Cytoreductive Surgery is Better Than Neoadjuvant Chemotherapy in Platinum-resistant Patients

    Research Square, 2024

    DOI 10.21203/rs.3.rs-4587958/v1 Açık erişimli tam metinKaynak: OpenAlex

  26. #104 Risk factors for sentinel lymph node metastasis in endometrial cancer (TRSGO-SLN-010)

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.273 Kaynak: OpenAlex

  27. #668 Evaluation of vulvar squamous cell and glandular cell cancers, retrospective multicenter study

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.828 Kaynak: OpenAlex

  28. SUCCOR Nodes: May Sentinel Node Biopsy Determine the Need for Adjuvant Treatment?

    Annals of Surgical Oncology, 2023

    DOI 10.1245/s10434-023-13529-w PMID 37208571 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  29. Incidence and Risk Factors of Venous Thromboembolism in Patients Undergoing Surgery for Gynecologic Malignancies

    Istanbul Medical Journal, 2023

    DOI 10.4274/imj.galenos.2023.86143 Kaynak: OpenAlex

  30. 3–4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles

    Chemotherapy, 2023

    DOI 10.1159/000535755 PMID 38113873 1 atıf (Europe PMC) Kaynak: OpenAlex

  31. The Relationship Between Melatonin 1-2 Receptor Expression in Patients With Epithelial Ovarian Cancer and Survival

    International Journal of Gynecological Pathology, 2023

    DOI 10.1097/pgp.0000000000000968 PMID 37922887 Kaynak: OpenAlex

  32. Correspondence on ‘Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors’ by Musacchio et al

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-004943 PMID 37730730 Kaynak: OpenAlex

  33. #18 3–4 Cycles vs 6 Cycles NACT in advanced stage epithelial ovarian cancer

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.494 Kaynak: OpenAlex

  34. #934 Treatment in recurrent uterine sarcomas

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.391 Kaynak: OpenAlex

  35. #560 The relationship between tumor mean standard uptake value (SUVMAX) in preoperative PET/computed tomography and prognostic risk groups in endometrial cancer

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.346 Kaynak: OpenAlex

  36. #845 Clinicopathologic and surgical analysis of 1090 patients with borderline ovarian tumors: a turkish society gynecologic oncology (TRSGO) multi-institutional retrospective trial

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.658 Kaynak: OpenAlex

  37. #488 Factors affecting the optimal cytoreduction rate in primary and interval operations of patients with advanced stage over cancer: creating a new scoring system for optimal cytoreducation

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.589 Kaynak: OpenAlex

  38. #17 The relationship between melatonin 1–2 receptor expression in patients with epithelial ovarian cancer and survival

    International Journal of Gynecological Cancer, 2023

    DOI 10.1136/ijgc-2023-esgo.493 Kaynak: OpenAlex

  39. Diagnostic accuracy of sentinel node biopsy in non-endometrioid, high-grade and/or deep myoinvasive endometrial cancer: A Turkish gynecologic oncology group study (TRSGO-SLN-006)

    Gynecologic Oncology, 2022

    DOI 10.1016/j.ygyno.2022.01.009 PMID 35033380 9 atıf (Europe PMC) Kaynak: OpenAlex

  40. EP155/#329 Deep cervical injection: a novel technique to increase bilateral sentinel lymph node detection rate in endometrial cancer patients with indocyanine green (TRSGO-SLN-008)

    International Journal of Gynecological Cancer, 2022

    DOI 10.1136/ijgc-2022-igcs.246 Kaynak: OpenAlex

  41. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.22.01003 PMID 35658487 342 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  42. SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer

    Annals of Surgical Oncology, 2022

    DOI 10.1245/s10434-022-11671-5 PMID 35430668 15 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  43. Diagnostic and prognostic role of TFF3, Romo-1, NF-кB and SFRP4 as biomarkers for endometrial and ovarian cancers: a prospective observational translational study

    Archives of Gynecology and Obstetrics, 2022

    DOI 10.1007/s00404-022-06563-8 PMID 35461390 14 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  44. SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer

    International Journal of Gynecological Cancer, 2022

    DOI 10.1136/ijgc-2022-003790 PMID 36583728 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  45. The relationship between tumor mean standard uptake value (SUVmax) in preoperative PET/computed tomography and prognostic risk groups in endometrial cancer

    Nuclear Medicine Communications, 2022

    DOI 10.1097/mnm.0000000000001654 PMID 36729416 4 atıf (Europe PMC) Kaynak: OpenAlex

  46. Juvenile granulosa cell tumor: 20 years’ experience of a Tertiary Center

    Ginekologia Polska, 2022

    DOI 10.5603/gp.a2022.0107 PMID 36748172 3 atıf (Europe PMC) Kaynak: OpenAlex

  47. Could the Long-Term Oncological Safety of Laparoscopic Surgery in Low-Risk Endometrial Cancer also Be Valid for the High–Intermediate- and High-Risk Patients? A Multi-Center Turkish Gynecologic Oncology Group Study Conducted with 2745 Endometrial Cancer Cases. (TRSGO-End-001)

    Current Oncology, 2021

    DOI 10.3390/curroncol28060368 PMID 34898563 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  48. 750 Diagnostic accuracy of sentinel node biopsy in non-endometrioid, high-grade and/or deep myoinvasive endometrial cancer (TRSGO-SLN-006)

    International Journal of Gynecological Cancer, 2021

    DOI 10.1136/ijgc-2021-esgo.190 Kaynak: OpenAlex

  49. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.11.013 PMID 34861371 133 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  50. Impact of cytoreductive surgery on survival of patients with low‐grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO‐OvCa‐001)

    Journal of Surgical Oncology, 2021

    DOI 10.1002/jso.26450 PMID 33657253 6 atıf (Europe PMC) Kaynak: OpenAlex